DNA

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

Retrieved on: 
Monday, August 8, 2022 - 9:30pm

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the quarter ended June 30, 2022, its recent business highlights, and a preview of anticipated select milestones.

Key Points: 
  • Sutro expects to report additional data on efficacy, safety, and durability from the dose-expansion cohort, together with the design of a potential registrational study, in the second half of 2022.
  • As of June 30, 2022, Sutro held approximately 1.6 million shares of Vaxcyte common stock, with a fair value of $34.0 million.
  • Total operating expenses for the quarter ended June 30, 2022 were $47.5 million, as compared to $37.9 million for the same period in 2021.
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Waldencast plc to Report Second Quarter and First Half 2022 Financial Results on August 11th

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (Waldencast), a global multi-brand beauty and wellness platform, today announced that it will hold a conference call to discuss its second quarter and first half 2022 earnings results on Thursday, August 11, 2022 at 8:00am ET.

Key Points: 
  • NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (Waldencast), a global multi-brand beauty and wellness platform, today announced that it will hold a conference call to discuss its second quarter and first half 2022 earnings results on Thursday, August 11, 2022 at 8:00am ET.
  • The second quarter and first half 2022 earnings press release will be issued prior to the start of the call.
  • The conference call will be webcast live and can be accessed at https://ir.waldencast.com/ .
  • The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup.

Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2022.

Key Points: 
  • Q2 2022 revenue $17.9 million, 37% y/y growth
    MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company, today announced its financial results for the second quarter ending June 30, 2022.
  • Akoya delivered another quarter of strong financial performance with record revenue and system placements in the second quarter, said Brian McKelligon, Chief Executive Officer, Akoya Biosciences.
  • Product revenue was $14.2 million in the second quarter of 2022, compared to $10.7 million in the prior year period; an increase of 33%; within product revenue, instrument revenue was $9.5 million and reagent revenue was $4.5 million for the quarter.
  • Akoya will host a conference call today, August 8, 2022, at 5:00 p.m. Eastern Time to discuss its second quarter 2022 financial results.

Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

ET to provide financial results and corporate updates for the fiscal third quarter of 2022.

Key Points: 
  • ET to provide financial results and corporate updates for the fiscal third quarter of 2022.
  • Participants should ask to be connected to the Applied DNA Earnings Conference Call.
  • The conference call and accompanying presentation slides will also be webcast and can be accessed from the News & Events section of the Applied DNA website at https://investors.adnas.com/ .
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").

Quantum-Si Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:02pm

Research and development expenses were $18.5 million in the second quarter of 2022, compared to $13.1 million in the second quarter of 2021.

Key Points: 
  • Research and development expenses were $18.5 million in the second quarter of 2022, compared to $13.1 million in the second quarter of 2021.
  • Selling, general and administrative expenses were $11.7 million in the second quarter of 2022, compared to $19.1 million in the second quarter of 2021.
  • Net loss was $32.4 million in the second quarter of 2022, compared to a net loss of $35.7 million in the second quarter of 2021.
  • Quantum-Si will host a conference call to discuss its second quarter 2022 financial results on Monday, August 8, 2022, at 4:30 PM Eastern Time.

Applied DNA Announces Closing of Upsized $12 Million Public Offering

Retrieved on: 
Monday, August 8, 2022 - 6:15pm

The gross proceeds to the Company from the offering were $12 million before deducting the placement agents fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from the offering were $12 million before deducting the placement agents fees and other offering expenses payable by the Company.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The offering was made only by means of a prospectus, which is part of the effective registration statements.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").

Alpha Motor Corporation Unveils CAMP - Collaborative Adventure Mobility Platform, An Innovative Digital Twin Experience

Retrieved on: 
Monday, August 8, 2022 - 4:30pm

Digital twin is a virtual creation that is identical to an existing physical object or experience in real-time.

Key Points: 
  • Digital twin is a virtual creation that is identical to an existing physical object or experience in real-time.
  • Throughout the CAMP site, featured brands showcase a digital twin of physical products that are available for purchase at each respective online store.
  • "CAMP by Alpha Motors is an innovative platform that represents the future of 'Move Humanity' culture.
  • This is the soul and DNA of Alpha," said Alpha Motor Corporation.

NewPoint Real Estate Capital and Morgan Properties Launch NewPoint Impact Providing Innovative Suite of Affordable Housing Financing Solutions

Retrieved on: 
Monday, August 8, 2022 - 4:00pm

NewPoint Real Estate Capital (NewPoint), a pioneering real estate finance company, announces the launch of NewPoint Impact, a proprietary affordable housing lending platform that pairs private capital with government-subsidized products to deliver an innovative set of next-generation affordable housing financing solutions.

Key Points: 
  • NewPoint Real Estate Capital (NewPoint), a pioneering real estate finance company, announces the launch of NewPoint Impact, a proprietary affordable housing lending platform that pairs private capital with government-subsidized products to deliver an innovative set of next-generation affordable housing financing solutions.
  • NewPoint Impact will finance the construction and/or acquisition/rehabilitation of affordable housing through a variety of financial products, including:
    NewPoint Impact 4% Tax-Exempt Bond Financing.
  • NewPoint Impact will provide construction or acquisition/rehabilitation financing, and, upon conversion, NewPoint Impact will underwrite FHA 223(f) permanent financing.
  • NewPoint Real Estate Capital ( NewPoint ) is a prominent commercial real estate finance company delivering lending solutions to investors of multifamily, affordable housing, seniors housing, healthcare, and manufactured housing properties nationwide.

Laser Technology Market worth $25.6 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 8, 2022 - 2:30pm

CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Laser Technology Market size is estimated to be USD 16.7 billion in 2022 and is projected to reach USD 25.6 billion by 2027, at a CAGR of 8.9%,according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Laser Technology Market size is estimated to be USD 16.7 billion in 2022 and is projected to reach USD 25.6 billion by 2027, at a CAGR of 8.9%,according to a new report by MarketsandMarkets.
  • Additionally, laser engraving and marking systems are also used for development of smart cards and unique identification cards.
  • In the coming years, laser and laser systems are expected to provide support troops with additional security against artillery, rockets, drones, mortars, and cruise missiles.
  • Additionally, increasing patients suffering from ophthalmic diseases in the region resulting in increasing demand for laser-based treatments is another factor driving the laser technology market.

Laser Technology Market worth $25.6 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, August 8, 2022 - 2:30pm

CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Laser Technology Market size is estimated to be USD 16.7 billion in 2022 and is projected to reach USD 25.6 billion by 2027, at a CAGR of 8.9%,according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Aug. 8, 2022 /PRNewswire/ -- Laser Technology Market size is estimated to be USD 16.7 billion in 2022 and is projected to reach USD 25.6 billion by 2027, at a CAGR of 8.9%,according to a new report by MarketsandMarkets.
  • Additionally, laser engraving and marking systems are also used for development of smart cards and unique identification cards.
  • In the coming years, laser and laser systems are expected to provide support troops with additional security against artillery, rockets, drones, mortars, and cruise missiles.
  • Additionally, increasing patients suffering from ophthalmic diseases in the region resulting in increasing demand for laser-based treatments is another factor driving the laser technology market.